海看股份(301262.SZ):積極響應總局“微短劇+”創作計劃,重點打造海看普法短劇廠牌
格隆匯4月1日丨海看股份(301262.SZ)在投資者互動平臺表示,公司積極響應總局“微短劇+”創作計劃,重點打造海看普法短劇廠牌,同時在微短劇+品牌、微短劇+非遺方向進行項目落地;開發完成“海看劇場”APP並在各手機應用市場正式上線,拓寬觀看渠道;2024年公司承接短劇拍攝100餘部,參與出品的精品微短劇在山東衛視上星播出。目前,公司短劇業務仍在穩步推進中,在公司整體營收中佔比較小,預計不會對當期業績產生重大影響。關於公司業務的具體情況,請以公司在指定媒體發佈的定期報告爲準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.